Evaluation of a new antituberculous agent. Capreomycin sulfate (capastat sulfate).
D000995:Antitubercular Agents / Q000627:therapeutic use*; D002207:Capreomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D003638:Deafness / Q000139:chemically induced; D004352:Drug Resistance, Microbial; D007758:Ear, Inner / Q000187:drug effects; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000139:chemically induced; D008099:Liver / Q000187:drug effects; D014012:Tinnitus / Q000139:chemically induced; D014376:Tuberculosis / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced
D000995:Antitubercular Agents; D002207:Capreomycin